Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Brittany Lancellotti, DVM, DACVD, broke down the treatments for canine allergic dermatitis, including through song, in her lecture at WVC 2025 ...

Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...